2018 Annual Meeting Presentations

State of the Network          

Maternal Isoniazid Preventive Therapy for Tuberculosis (TB) Prevention in High Burden TB/HIV settings: Results of the IMPAACT P1078 Trial

Precision Vaccines: Rationale for Early Life Immunization Against HIV

NIAID: State of the Institute and Priorities for HIV/AIDS Research

Imaging the Dynamics and Localization of Immune Cells in situ – New Insights and Technologies Useful to the HIV Cure Community

Ronald Germain, MD, PhD

Optimizing the Impact of PEPFAR

Welcome and Overview of Treatment Scientific Agenda

Overview of Recent Findings on Dolutegravir

Implications of Recent DTG Findings for IMPAACT 2010/VESTED

Panel Discussion: Clinical Implications and Community Perspectives

Moderator: Elaine Abrams

P1026s, Focus on TAF: Pharmacokinetic Properties of Antiretrovirals Therapy During Pregnancy

P1093: Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572 (Dolutegravir), a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents

Ted Ruel

P1101: Phase I/II Dose-Finding, Safety, Tolerance, & PK Study of Raltegravir-Containing ART Regimen in HIV-Infected & TB Co-Infected Children

P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants

P1110: A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-Exposed Infants at High Risk

Updates on Treatment Studies Enrolling, Pending and In-development

Elaine Abrams and
Ted Ruel

Welcome and Overview of Tuberculosis Scientific Agenda

P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIVUninfected Infants, Children and Adolescents with MDR-TB Disease

Anneke Hesseling

IMPAACT 2005: A Phase I/II Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-infected and HIV-uninfected Children with MDR-TB

Ethel Weld

IMPAACT 2020: Shortened Oral Treatment for Multidrug-Resistant Tuberculosis in Infants, Children and Adolescents (SMaRT Kids): A Phase III Randomized Multi-center Trial

Drug Susceptible TB: Opportunities and Priorities

Update and Way Forward for Phase I/II Maternal and Pediatric Prevention Studies:

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-infected Women in High TB Incidence Settings

A5279: One month of Rifapentine/Isoniazid to Prevent TB in People with HIV: BRIEF-TB

Amita Gupta

IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection

Jyoti Mathad

P1026s: Pharmacokinetic Properties of Antiretroviral Therapy during Pregnancy

Jennifer Hughes

TB Pregnancy Registry

Tuberculosis Scientific Committee

Innovative statistical methods for Phase III Tuberculosis Trials in Children

Soyeon Kim

State of the Art: TB drug pharmacokinetics at the site of disease

Veronique Dartois

Regulatory Perspectives from the FDA on Priorities and Methods for TB Trials in Children and Pregnant Women

Lynne Yao

Roundtable Discussion: Future MDR-TB Trials

Tuberculosis Scientific Committee

End Organ Disease and Inflammation Transformative Science Group

Turner Overton & Netanya Utay

Effects of Broadly Neutralizing Antibody Combinations in HIV-1 Infection

Marina Caskey

Lynda Stranix-Chibanda

PROMISE: Progress to date, plans for the future, and gaps remaining for perinatal HIV prevention

Mary Glenn Fowler

Role of Maternal Viral Load in HIV Transmission in Promise

Patricia Flynn

PROMISE Maternal Study of HIV Drug Resistance

Lisa Frenkel

Use of Non-Human Primates in TB vaccine research

Shelby O’Connor

Coleen Cunningham

Anne-Marie Demers

Lisa Frenkel

David Shapiro

Anne Purfield

Anne Leach; pSMILE

Derek Armstrong

Robin Difrancesco

Ed Acosta

Heather Sprenger

Barbara Petrie and Teri Andresen